Sign in
Taking people in United StatesPhase 1

Tests pasritamig with other drugs for advanced prostate cancer

Tests pasritamig with other drugs in men with metastatic prostate cancer.

Key facts

Who runs it
Janssen Research & Development, LLC
Where
Brooklyn, Grand Rapids, Mineola, New York, Philadelphia, Sarasota, and St Louis, United StatesSee the 7 sitesAlso in 2 other countries, 8 sites
Registry title
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Status
Recruiting
Phase
Phase 1
People taking part
300 people, planned
Started
26 Apr 2023
Expected to end
23 May 2028
Type of study
Interventional
Treatments tested
  • Pasritamig
  • Cetrelimab
  • Cabazitaxel
  • Docetaxel
  • Apalutamide
  • Enzalutamide
  • Darolutamide
  • Abiraterone acetate plus prednisone (AAP)
  • Lutetium Lu-177 vipivotide tetraxetan
  • JNJ-101556143
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with metastatic prostate cancer. It tests pasritamig together with other cancer drugs.

Age
18 years or older
Sex
Men only
Disease stage
Metastatic castration-resistant prostate cancer (adenocarcinoma of the prostate), or in Part 2H metastatic hormone-sensitive prostate cancer. Disease must be measurable or evaluable, except in Part 2H.
Earlier treatment
Depends on the part. Most parts need at least 1 earlier androgen receptor pathway inhibitor (apalutamide, enzalutamide, darolutamide or abiraterone acetate). Cabazitaxel parts also need earlier docetaxel. Lutetium Lu-177 parts need no earlier chemotherapy or radioligand therapy for mCRPC.
Biomarker or test result
In most parts 2D-G, 2I, 2J and 2K, PSA of at least 2 ng/mL. In Part 2H, PSA above 0.2 ng/mL on 6 to 24 months of treatment with a next generation ARPI.

Main reasons for not taking part

  • Active autoimmune disease in the past 12 months that needs drugs to suppress the immune system
  • Side effects from earlier cancer treatment that have not eased to Grade 1 or baseline (some exceptions)
  • Solid organ or bone marrow transplant
  • Known allergy or intolerance to any component of the study drugs
  • Significant infections or serious lung, heart or other medical conditions

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Part 1 A-G, 1I, 1J, and 1K (all combination treatments) and Parts 2B-C (cabazitaxel, docetaxel): Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by prostate cancer working group 3 (PCWG3); Parts 2D-G, 2I, 2J, and 2K (apalutamide, enzalutamide, darolutamide, abiraterone acetate + prednisone [AAP], lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143): mCRPC: Histologically confirmed adenocarcinoma of the prostate as defined by PCWG3, with a minimum PSA of 2 nanogram [ng]/milliliter (mL); Part 2H (apalutamide): metastatic hormone-sensitive prostate cancer(mHSPC) with PSA greater than (>) 0.2 ng/mL on 6 to 24 months of treatment with a next generation ARPI (apalutamide, enzalutamide, darolutamide, or abiraterone)
  • Measurable or evaluable disease, except for Part 2H
  • (a) Part 1A (cetrelimab) - Prior treatment for mCRPC with at least 1 prior androgen receptor pathway inhibitors (ARPI) (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), or chemotherapy (example, docetaxel). (b) Part 1C and 2C (docetaxel), Part 1D (apalutamide), Part 1E and 2E (enzalutamide), Part 1F and 2F (darolutamide), and Part 1G, 2G (AAP), and Part 1K \& 2K (JNJ-101556143)- Prior treatment with at least 1 prior ARPI (that is, apalutamide, enzalutamide, darolutamide, or abiraterone acetate). (C) Part 1B and 2B (cabazitaxel) - Prior treatment with at least 1 prior ARPI (ie, abiraterone acetate, apalutamide, enzalutamide, darolutamide) and docetaxel. (d) Part 2D (apalutamide) - Prior treatment with at least 1 prior ARPI (e) Part 2H (apalutamide)- Participant may have received up to 6 cycles of docetaxel. The last dose of docetaxel must be administered at least 2 months prior to enrollment (f) Parts 1I, 1J, 2I \& 2J (lutetium Lu-177 vipivotide tetraxetan)- Prior treatment with at least 1 ARPI (abiraterone acetate, enzalutamide, darolutamide, or apalutamide). Participant must not have received prior cytotoxic chemotherapy or prior radioligand therapy (RLT) for mCRPC
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ functions

Who cannot take part

  • Active autoimmune disease within the 12 months prior to signing consent that requires systemic immunosuppressive medications
  • Toxicity related to prior anticancer therapy that has not returned to Grade less than or equal to (<=) 1 or baseline levels (except for alopecia, vitiligo, Grade <=2 peripheral neuropathy)
  • Solid organ or bone marrow transplantation
  • Known allergies, or intolerance to any of the components (example, excipients) of pasritamig, cetrelimab (Part 1A), cabazitaxel, Part 1B and 2B , docetaxel Part 1C and 2C , apalutamide (Part 1D and 2D and Part 2H), enzalutamide (Part 1E and 2E), darolutamide (Part 1F and 2F), or AAP (Part 1G and 2G), lutetium Lu-177 vipivotide tetraxetan (Parts 1I, 1J, 2I, and 2J), or JNJ-101556143 (Parts 1K \& 2K)
  • Significant infections or serious lung, heart or other medical conditions

Where in United States

Also in 2 other countries, 8 sites

  • Perlmutter Cancer Center at NYU Langone BrooklynBrooklyn, United StatesTaking people
  • START | MidwestGrand Rapids, United StatesTaking people
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineola, United StatesTaking people
  • NYU Langone HealthNew York, United StatesTaking people
  • Sidney Kimmel Cancer Center - Jefferson HealthPhiladelphia, United StatesTaking people
  • Florida Cancer SpecialistsSarasota, United StatesTaking people
  • Washington University School of MedicineSt Louis, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).

The group in the trial

  • JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)Treatment being tested

    Participants will receive pasritamig (JNJ-78278343) and combination agent (cetrelimab, cabazitaxel, docetaxel, apalutamide, enzalutamide, Darolutamide, abiraterone acetate plus prednisone, Lutetium Lu-177 vipivotide tetraxetan and JNJ-101556143) during Part 1 (dose escalation). The dose of pasritamig (JNJ-78278343) will be escalated sequentially until a recommended phase 2 regimen (RP2R). Participants will receive pasritamig (JNJ-78278343) and combination agent treatment at the putative RP2R in Part 2 (dose expansion).

    Treatment: Pasritamig, Cetrelimab, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP), Lutetium Lu-177 vipivotide tetraxetan, and JNJ-101556143

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
Plain-language title
Tests pasritamig with other drugs for advanced prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 November 2026